Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.
The Paragraph IV certification sought is with respect to applicable patents listed in the U.S. FDA’s Orange Book. Granules said it has also issued the requisite notice to the relevant parties in accordance with U.S. regulatory requirements.
· 10/7/2026, 10:27:21 AM· 2 min read
The Paragraph IV certification sought is with respect to applicable patents listed in the U.S. FDA’s Orange Book. Granules said it has also issued the requisite notice to the relevant parties in accordance with U.S. regulatory requirements.
Read original story →Related stories
business
Gradiant bets big on India, secures five contracts, including semiconductor fab
business
RBI has done what it can with interest rates, but heavy lifting on inflation will fall on government
business
Royal Mail plans to cut 2,500 head office jobs
business